Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development, commercialization, and marketing of dermatological products, primarily for the treatment of precancerous and cancerous skin conditions. The company operates within the dermatology and oncology-supportive care segments of the pharmaceutical industry. Its core commercial focus is on photodynamic therapy (PDT) products used in dermatology practices across the United States.
The company’s primary revenue driver is AMELUZ®, a topical prescription drug approved for use with the BF-RhodoLED® lamp for PDT treatment of actinic keratosis (AK) on the face and scalp. Biofrontera Inc. serves dermatologists, dermatology clinics, and specialized medical practices, positioning itself as a niche provider with an integrated drug-and-device PDT platform. The company was incorporated in 2015 and became publicly listed in the United States, evolving from its role as the American commercialization arm of Biofrontera AG, its former parent company based in Germany.
Business Operations
Biofrontera Inc.’s operations center on the commercialization and distribution of prescription dermatology products in the United States. Its business model combines pharmaceutical product sales with associated medical device utilization, generating revenue primarily through U.S. sales of AMELUZ® and the BF-RhodoLED® PDT lamp. The company does not engage in large-scale drug discovery but focuses on regulatory approval, marketing, physician education, and sales execution.
The company operates exclusively in the U.S. market, with manufacturing and certain supply chain functions supported through contractual relationships and historical ties to Biofrontera AG. Biofrontera Inc. controls U.S. commercialization rights for its key products and maintains a dedicated dermatology-focused sales force. Public disclosures indicate no material joint ventures, and operations are conducted primarily through the parent operating entity rather than a broad subsidiary structure.
Strategic Position & Investments
Biofrontera Inc.’s strategic direction emphasizes expanding adoption of PDT for actinic keratosis by increasing physician awareness, improving reimbursement access, and deepening penetration within dermatology practices. Growth initiatives have centered on commercial execution rather than acquisitions, with investments directed toward sales force expansion, marketing programs, and clinical data generation to support broader use of AMELUZ®.
The company has historically relied on licensing and supply agreements related to Biofrontera AG, though governance and ownership ties have changed over time following legal disputes and restructuring. Emerging strategic focus areas include lifecycle management of existing products and potential label expansions, although public sources indicate limited diversification beyond dermatology and no confirmed material acquisitions. Where future pipeline development has been discussed, available public data remains limited and inconclusive.
Geographic Footprint
Biofrontera Inc. operates primarily within the United States, which represents its sole commercial market and operational focus. The company is headquartered in the United States, with corporate offices and sales operations supporting nationwide distribution to dermatology practices.
While Biofrontera Inc. does not maintain international commercial operations, its historical and contractual relationships with Europe, particularly Germany, have influenced its product portfolio and supply chain. Any international exposure is indirect and tied to manufacturing, intellectual property origins, or legacy agreements rather than active foreign market participation.
Leadership & Governance
Biofrontera Inc. is led by an executive team with experience in pharmaceuticals, dermatology commercialization, and public company governance. Leadership has emphasized disciplined cost management, targeted commercial growth, and restoring financial stability following periods of operational and legal complexity.
Key executives include:
- Hermann Lübbert – Chief Executive Officer
- Thomas Schaffer – Chief Financial Officer
- Erik Malmstrom – Chief Commercial Officer
- Michael Koenig – Chief Medical Officer
The company operates under a shareholder-elected board of directors and follows U.S. public company governance standards, with strategic oversight focused on profitability, regulatory compliance, and long-term value creation within its specialized dermatology niche.